Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus
The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.
- IRB Number: 1810897000
- Research Study Identifier: TX10301
- Principal Investigator: Linda DiMeglio, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required